Two additional cases of metformin-associated encephalopathy in patients with end-stage renal disease undergoing hemodialysis

Hemodial Int. 2013 Jan;17(1):111-5. doi: 10.1111/j.1542-4758.2012.00698.x. Epub 2012 Apr 20.

Abstract

We report on two additional cases of metformin-associated encephalopathy in patients with end-stage renal disease (ESRD) undergoing hemodialysis. Two patients were seen at our hospital with abnormal neurological signs and symptoms. Magnetic resonance imaging (MRI) revealed the same pattern of high signal intensity in both basal ganglia in T2-weighted images in the two patients. The two patients had started taking metformin 5 and 6 weeks earlier at the same dose of 1000 mg per day. Metformin was immediately stopped, and regular hemodialysis was conducted. Their signs and symptoms resolved completely after these measures. The high signal intensity in both ganglia in T2-weighted MRI also disappeared. We should suspect metformin-induced encephalopathy and withdraw the drug when presented with diabetic patients with chronic kidney disease and neurological signs and symptoms of unknown cause.

Publication types

  • Case Reports

MeSH terms

  • Brain Diseases / complications
  • Brain Diseases / pathology
  • Contraindications
  • Female
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / therapy
  • Magnetic Resonance Imaging
  • Male
  • Metformin / adverse effects*
  • Middle Aged
  • Renal Dialysis*
  • Renal Insufficiency, Chronic / complications*
  • Renal Insufficiency, Chronic / therapy

Substances

  • Hypoglycemic Agents
  • Metformin